Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are important agents for the treatment of HIV infection, demonstrating superiority compared with protease-inhibitor-based regimens in antiretroviral therapy (ART)-naive patients in several large randomized trials [1, 2] . Data from the 2NN study, a large multinational randomized comparison of the NNRTI efavirenz (EFV) with nevirapine (NVP; dosed both twice daily and once daily), indicate that ART-naive patients achieve a good antiviral treatment response after 48 weeks of treatment with either an NVP-or EFV-based regimen [3] .
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are important agents for the treatment of HIV infection, demonstrating superiority compared with protease-inhibitor-based regimens in antiretroviral therapy (ART)-naive patients in several large randomized trials [1, 2] . Data from the 2NN study, a large multinational randomized comparison of the NNRTI efavirenz (EFV) with nevirapine (NVP; dosed both twice daily and once daily), indicate that ART-naive patients achieve a good antiviral treatment response after 48 weeks of treatment with either an NVP-or EFV-based regimen [3] .
NVP has a long plasma half-life and achieves high steady-state plasma concentrations relative to the 50% inhibitory concentration, which makes NVP a good candidate for once-daily dosing. Although only registered for Introduction use with a dosage of 200 mg twice daily, NVP is often prescribed once daily in clinical practice in combination with two once-daily nucleoside reverse transcriptase inhibitors (NRTIs), such as lamivudine (3TC), emtricitabine (FTC), abacavir, didanosine (ddI) and tenofovir (TDF).
Once-daily usage of NVP has been associated with higher incidences of hepatobiliary toxicities and skin rashes [3] . Between 6% and 7% of patients initiating twice-daily NVP-based ART need to stop NVP within 18 weeks because of such events. Furthermore, early virological failure in patients treated with once-daily NVP in combination with TDF and 3TC was recently described [4, 5] . Another study reported that NVP dosed twice-daily in combination with FTC and TDF had poor antiretroviral efficacy [6] . Because of these reports of virological non-response and early virological failure, recent US Department of Health and Human Services guidelines recommend that NVP, TDF plus FTC (or 3TC) should be used with caution [7] .
To address these issues, we performed a retrospective multicohort study including all participants of the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort, the Canadian HAART Observational Medical Evaluation and Research (HOMER) cohort, and the Swiss HIV Cohort Study (SHCS) who commenced ART that included NVP. We assessed the risk of discontinuation of NVP because of hypersensitivity reaction (HSR) and its relationship to NVP dosing schedule. We investigated virological failure, including a subgroup analysis to investigate treatment efficacy of two specific types of NVP-containing regimens: TDF/3TC or TDF/FTC, plus NVP once daily compared with regimens composed of a thymidine analogue, plus 3TC or FTC, plus NVP twice daily.
Methods
Data from all 22 Dutch hospitals providing antiretroviral treatment to HIV-infected individuals are anonymously recorded in the database of the ATHENA cohort [8] . The ATHENA database includes information on patient demographic and biological characteristics, HIV-related clinical events, detailed treatment data as well as data on adverse events for which antiretroviral medication is modified.
The SHCS, established in 1988, is a national prospective study based on voluntary participation of persons infected with HIV type-1 (HIV-1). The rationale, organization and baseline characteristics of the study have been described elsewhere in detail [9] , and a continuously updated description can be found on the SHCS website [10] .
The HOMER study is a prospective observational cohort of all ART-naive patients aged 18 years or older initiating highly active antiretroviral therapy in British Columbia, Canada [11] .
For this analysis we selected all HIV-1-infected patients who had started NVP between April 1998 until censoring time in April 2007. We identified all patients who had discontinued the use of NVP because of an adverse event compatible with an NVP-associated HSR within 18 weeks after first starting NVP [12] . All skin rashes and/or hepatotoxicity occurring during the follow-up time and leading to the discontinuation of NVP were scored as NVP-associated HSR. Reasons for discontinuation are systematically collected and validated in the ATHENA, SHCS and the HOMER databases and include discontinuation because of skin rash and hepatotoxicity as separately coded events. CD4 + T-cell counts were classified as 'high' (>250 cells/ mm 3 for females and >400 cells/mm 3 for males) or 'low' at the start of NVP-based treatment. CD4 + T-cell counts were also classified on the basis of the last available pretreatment CD4 + T-cell count being either 'high' or 'low' using the same criteria. In the study period (April 1998 to April 2007) several quantification methods for HIV-1 RNA were used, but the majority of measurements (80.7%) were done using ultrasensitive assays with a lower limit of quantification of 40 or 50 copies/ ml. For the toxicity analysis 'undetectable' was defined as having an undetectable result in the assay that was actually used.
Baseline was defined as the moment NVP was initiated. Categorical variables were compared between groups using the χ 2 or Fisher's exact statistic. Continuous variables were compared using the Wilcoxon rank-sum test. Patients who discontinued the use of NVP within 14 days (that is, while still using the lead-in dose of 200 mg oncedaily) could not be classified into either the 400 mg oncedaily or 200 mg twice-daily groups, and were excluded from the analyses. The incidence of treatment-limiting HSR between 2 and 18 weeks after first NVP initiation was compared between patients using NVP twice daily or once daily using logistic regression models. All models included NVP dosing schedule (400 mg once daily versus 200 mg twice daily) and calendar year of starting NVP, and were stratified for cohort. Several parameters (gender, ethnicity, age, CD4 + T-cell count at the start of first combination ART, and CD4 + T-cell count and HIV-1 RNA at the start of NVP) suspected to be associated with the risk of developing NVP-associated HSR were investigated by stepwise inclusion into the model, and statistical interactions between covariables were formally tested.
All analyses of antiretroviral efficacy were performed separately for each of the three following groups: treatment-naive patients, treatment-experienced patients with detectable HIV-1 RNA levels at the start of NVP and treatment-experienced patients with undetectable HIV-1 RNA levels at the start of NVP. Time to loss of virological response (TLOVR) was analysed using a KaplanMeier survival analysis. Loss of virological response was defined as having a HIV-1 RNA level >400 copies/ ml to avoid classifying transient low-level viraemia (socalled 'blips') as virological failures. The influence of NVP dosing schedule on the TLOVR was investigated using multivariate Cox models that were stratified for cohort and were adjusted for calendar year of initiation of NVP and other known risk factors, such as HIV-1 RNA and CD4 + T-cell count. To investigate the possible influence of a low CD4 + T-cell count (<100 cells/mm 3 ) and high HIV-1 RNA (>5 log 10 copies/ml), we added terms for low CD4 + T-cell count and high HIV-1 RNA to the Cox model and fitted interaction terms between the used dose of NVP and the terms for CD4 + T-cell and HIV-1 RNA. The proportional hazards assumption was tested by visual inspection of log-log plots. Changes in CD4 + T-cell count were compared between NVP twicedaily and once-daily dosing using mixed-effects models (PROC MIXED; SAS Institute Inc., Cary, NC, USA).
All analyses were performed using SAS version 9.1 (SAS Institute Inc.) and SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).
Results

Population
A total of 5,782 patients from the Dutch ATHENA (n=3,808, 65.9%), Swiss SHCS (n=1436, 24.8%), and the Canadian HOMER (n=538, 9.3%) cohorts, commencing any combination ART including NVP were included. A total of 146 (2.5%) patients discontinued the use of NVP during the lead-in period of 14 days, leaving 5,636 patients for the main analysis. Baseline characteristics are shown in Table 1 : 75.3% were male, median (interquartile range [IQR]) age was 39.7 years (34.2-46.7) and median (IQR) CD4 + T-cell count at NVP initiation was 294 cells/mm 3 (175-500). Overall 1,185 (21.0%) patients were treatment-naive at baseline and 86.3% of the patients commencing NVP were initiated with a twice-daily regimen. The most frequently used NRTIs were zidovudine or stavudine for the twice-daily group (80.5%) and TDF for the oncedaily group (60.2%). Median (IQR) follow-up time was 4.2 years (2.0-6.5).
Hypersensitivity reactions
Of the 146 (2.5%) patients who discontinued the use of NVP during the lead-in period of 14 days, 60 (1.7%) discontinued NVP because of HSR (data not shown). Of the remaining 5,636 patients, 497 (8.8%) discontinued NVP because of any toxicity between 2 and 18 weeks, whereas 268 (4.8%) discontinued NVP because of HSR. More patients discontinued NVP because of HSR in the once-daily group compared with the twice-daily group (6.3% versus 4.5%; P=0.036; Figure 1 ). HSR consisted of hepatotoxicity in 65 (1.2%) patients with no significant difference between the NVP twice-daily and once- Among the 734 patients who, after using a 200 mg twice-daily NVP-based regimen for some time, switched to a 400 mg once-daily regimen, only 3 (0.41%) had to discontinue NVP within 18 weeks after the switch because of HSR (2 rashes and 1 hepatotoxicity).
Efficacy
Antiretroviral efficacy was studied for treatment-naive patients (n=1,080), treatment-experienced patients starting NVP having undetectable HIV-1 RNA (n=1,819), and treatment-experienced patients having detectable HIV-1 RNA (n=2,225). A total of 343 patients had a missing baseline CD4 + T-cell or viral load, preventing their inclusion in the efficacy analysis. A total of 734 (13%) patients switched from a twice-daily NVP-based regimen to a once-daily regimen after a median (IQR) of 172 weeks (84-262) of NVP treatment and 6.5% switched from a twice-daily to a once-daily NVP regimen within 18 weeks after NVP initiation. At the moment of the switch, HIV-1 RNA was undetectable in 82.2% of patients and their median (IQR) CD4 + T-cell count was 460 cells/mm 3 (311-670). At 96 weeks, 84% of treatment-naive patients using a twice-daily regimen had undetectable HIV-1 RNA as compared with 86% of those on a once-daily regimen (P=0.540). Kaplan-Meier analysis showed no differences between the groups in time to become undetectable (log-rank P=0.76; data not shown). Adjusted Cox models confirmed these results (twice daily versus once daily hazard ratio [HR] 0.97; P=0.71).
In treatment-experienced patients who started NVP with detectable HIV-1 RNA levels, NVP once daily was associated with a better virological outcome at week 96 as compared with patients on NVP twice-daily dosing schedule (71% versus 52% of patients with undetectable HIV-1 RNA for the once-daily and twice-daily group, respectively; P<0.0001). Kaplan-Meier analysis of the TLOVR showed a significantly higher incidence of virological failure in the twice-daily group compared with the once-daily group (24.1% and 16.0% after 96 weeks of follow-up, respectively; log-rank P=0.006). However, the TLOVR was not significantly different in the adjusted Cox analysis, even after adjustment for 
30).
To test the assumption that once-daily NVP might be associated with a higher risk of treatment failure in patients with more advanced HIV-1, we investigated the relationship of low baseline CD4 + T-cell count and high baseline HIV-1 RNA with virological treatment failure in both treatment-naive and treatmentexperienced patients who started NVP with detectable HIV-1 RNA. Overall, 20% of treatment-naive patients had a CD4 + T-cell count <100 cells/mm 3 and 33% had a high HIV-1 RNA>5 log 10 copies/ml. Among treatment-experienced patients, these values were 21% and 23%, respectively. We found no statistically significant differences between patients using NVP once or twice daily with respect to the influence of markers of HIV-1 disease progression on the risk of virological failure (data not shown).
In treatment-experienced patients with undetectable HIV-1 RNA, we observed a significant difference in TLOVR between NVP prescribed twice daily or once daily until week 96 (23.8% versus 12.5%, respectively; log-rank P=0.003). However, similar to the TLOVR analysis for the experienced patients with detectable HIV-1 RNA, the apparent difference in TLOVR in the KaplanMeier analysis disappeared in the adjusted Cox analysis (twice daily versus once daily HR 1.29; P=0.30).
We performed a sensitivity analysis wherein virological success was defined as an undetectable viral load measurement using an ultrasensitive assay with a cutoff value ≤50 copies/ml. We excluded all the undetectable viral load measurements of the assays that did not have an ultrasensitive cutoff. Virological failure was defined as any detectable viral load measurement after having become undetectable. The Cox models for these sensitivity analyses again showed that risk of virological failure was not different for twice-versus once-daily NVP in treatment-naive patients (twice daily versus once daily HR 1.00; P=0.98), treatment-experienced patients experiencing treatment failure (twice daily versus once daily HR 1.06; P=0.30) or patients with undetectable HIV-1 RNA simplifying treatment with NVP (twice daily versus once daily HR 1.13; P=0.48).
There was a low incidence of virological failure in the following 2 years in patients who switched from NVP twice daily to once daily and who had undetectable HIV-1 RNA at the moment of switch: 9.3% in patients who were treatment-naive at the time they started NVP-based combination ART, and 9.2% in patients who were already treatment-experienced at the time they started NVP-based combination ART.
Immune reconstitution
There was no significant differences at 96 weeks in CD4 + T-cell count gains between the twice-daily and ; P=0.002) between the twice-daily and oncedaily groups in the treatment-experienced patients who started NVP with a detectable HIV-1 RNA, but this difference was no longer significant after adjusting for calendar year of NVP start (P=0.70).
Subgroup analysis of TDF-containing NVP-based once-daily regimen
From the total of 5,782 patients, we identified 377 patients who initiated combination ART with a once-daily regimen of NVP, 3TC or FTC plus TDF (TDF group), and 2,846 patients who initiated a twicedaily thymidine-analogue-based regimen (2TA group) together with 3TC or FTC. Baseline characteristics were similar to the whole cohort (data not shown). The median (IQR) CD4 + T-cell count at initiation of NVP was 310 cells/mm 3 (190-522), 1,294 (41.5%) patients had undetectable HIV-1 RNA at start of NVP. Median follow-up was 62 weeks in the TDF group compared with 266 weeks in the 2TA group. Overall, 27.9% (n=900) of the patients were treatment-experienced before starting NVP but had a detectable viral load, 27.9% (n=900) of them started in either group being antiretroviral naive and 37.3% (n=1,203) started an NVP-containing regimen while being already undetectable. A total of 220 (6.8%) patients had no baseline HIV-1 RNA data available and could not be evaluated. We found no difference between the TDF or 2TA groups in the number of patients with undetectable HIV-1 RNA at 96 weeks in the treatment-naive population (83.7% versus 88.1%; P=0.39) nor in the treatment-experienced group with undetectable baseline HIV-1 RNA (82.9% versus 87.9%; P=0.37). However, in the subgroup of treatment-experienced patients with detectable baseline HIV-1 RNA, the proportion of patients with undetectable HIV-1 RNA at 96 weeks was significantly different (91.1% versus 63.3% for the TDF and 2TA groups, respectively; P=0.0001). Logistic regression showed that after adjusting for baseline CD4 + T-cell count and calendar year at which NVP was initiated, the differences between the TDF and 2TA groups were not statistically significant anymore (Table 3) .
Discussion
Our results confirm previous studies showing that starting treatment with NVP once daily, as compared with twice daily, is associated with more frequent treatment-limiting HSR [3, 13] . However, we also showed that this increased risk is restricted to patients initiating NVP once daily while having detectable HIV-1 RNA, whereas patients initiating NVP once daily in the setting of already suppressed HIV-1 RNA actually have a statistically significantly lower risk. Furthermore, switching from a twice-daily NVP-based regimen to a once-daily NVP-based regimen appears to carry only a very small additional risk of developing a treatment-limiting HSR.
The pathogenesis of the increased risk of treatmentlimiting HSR in patients starting NVP once daily is unknown, but pharmacokinetic parameters, such as maximum plasma concentration of NVP was not related to adverse events in the 2NN study [14, 15] . The identified risks factors for treatment-limiting HSR in our study were similar to what other studies have found: higher nadir and current CD4 + T-cell count, female gender and Asian origin [3, [16] [17] [18] . Previous reports also suggested that patients starting NVP treatment with a suppressed HIV-1 RNA have a significantly lower incidence of HSR [19, 8] . The current analysis corroborates these findings.
We observed very few HSR in patients switching from a stable twice-daily NVP-based regimen to a once-daily NVP-based regimen. The protective effect of initiating once-daily NVP while HIV-1 RNA is already undetectable might partially explain this finding. However, among the 15% of patients with detectable HIV-1 RNA at the moment of switching from NVP twice daily to once daily, we also observed a low rate of HSR. In our cohort, most of these patients had been on a twice-daily regimen for ≥2 years before they switched to a once-daily dosing schedule. Whether, as is likely, a shorter period would also be safe, cannot reliably be deduced from our data. However, a recent clinical trial enrolled patients with ≥12 weeks of standard twicedaily NVP-based regimens and randomized them to either be simplified with a once-daily NVP regimen, or to continue the standard twice-daily NVP-based regimen [20] . This study did not reveal an increased risk of hepatotoxicity (0.7% versus 2.1% of the patients developed grade 3 or 4 increased aminotransferases in the twice-daily versus the once-daily group). These data support our observations and might support the choice of a shorter 'lead-in twice-daily' period prior to the use of once-daily NVP.
Our data suggests that NVP dosed once daily in clinical practice is at least as effective in suppressing HIV-1 replication as NVP prescribed twice daily. Treatment-experienced patients with detectable HIV-1 RNA commencing a regimen including once-daily NVP experience more rapid and sustained virological suppression, as well as a greater rise in CD4 + T-cell counts, although these differences did not reach statistical significance. Patients with more advanced HIV-1 disease who used NVP once-daily were not at greater risk of virological failure compared with similar patients using NVP twice-daily.
The 2NN study showed in an intent-to-treat analysis that the proportion of patients with HIV-1 RNA <50 copies/ml at week 48 was similar in the once-daily and twice-daily arms (70% once daily and 65.4% twice daily; P=0.24). Negredo et al. [21] included 196 treatment-experienced patients in a nonrandomized treatment-simplification trial, with patients switching (or continuing) various twice-daily regimens to once-daily NVP, and ddI plus TDF. At week 48, the proportion of patients with viral suppression in the once-daily and in the twice-daily group was similar [21] . Our findings are in line with those from previous trials [21, 22] .
In a randomized trial, Rey et al. [5] compared oncedaily 3TC, TDF and NVP with twice-daily zidovudine, 3TC and NVP. An unplanned interim analysis was performed after 71 patients had been enrolled. Because an unexpectedly high rate of early virological non-response was observed in the once-daily group (n=8, 22%), the study was permanently discontinued. Six patients out of eight virological non-responders harboured the K65R mutation at the time of treatment failure. Of interest, NVP trough concentrations were not different in the two arms, nor in patients with full virological suppression or those who experienced virological non-response in the once-daily group.
In our cohort, 377 patients were on a once-daily regimen containing TDF, 3TC or FTC, and NVP, and we compared them to 2,846 patients on a zidovudine or stavudine, 3TC or FTC, plus NVP twice-daily regimen. Virological efficacy was similar in the two groups. However, baseline characteristics were quite different in our cohort compared with the population of Rey et al. [5] . Baseline CD4 + T-cell counts were lower (194 cells/ mm 3 for Rey et al. [5] and 310 cells/mm 3 in our cohort), and HIV-1 RNA was >4 logs for Rey et al. [5] , whereas in our cohort 41% had undetectable HIV-1 RNA. This might (partially) explain the differences between our cohort study and the findings of Rey et al. [5] .
Our study has several limitations inherent to observational cohort studies. Several confounding variables such as CD4 + T-cell count were not equally distributed among the patients using NVP once daily or twice daily. Although our analyses were adjusted for several measured confounding variables there will always remain an unquantified level of residual confounding. When an antiretroviral agent is stopped because of an adverse event, only the adverse event directly responsible for the discontinuation is recorded. Also, because of the retrospective nature of our analysis, it can not be excluded that some of the reported rashes or increased aminotransferases might be the result of other factors not related to the use of NVP. Low-grade skin rashes that did not result in a modification of antiretroviral treatment might not have been captured in every instance; hence, the overall incidence of all-grade skin rashes could not reliably be determined.
Our results are relevant for the antiretroviral treatment programmes in the developing world. NVPbased regimens account for >90% of treatment prescription in resource-limited settings [23] . As TDF is expected to replace stavudine as a preferred NRTI in first-line regimens worldwide, it is necessary to investigate the safety and efficacy of a NVP-based first-line treatment including TDF [24] .
We conclude that the higher incidence of treatmentlimiting HSR remains a significant obstacle to widespread use of NVP dosed once daily in patients having detectable plasma HIV-1 RNA at the moment of initiation of NVP, that is, treatment-naive patients and patients experiencing treatment failure who start second-line NVP-based treatment. However, initiation of once-daily NVP in patients who already have suppressed HIV-1 replication, and also patients switching from a stable twice-daily NVP-based regimen to a once-daily NVP-based regimen, has a favourable safety profile. We did not identify efficacy concerns in patients using NVP in a once-daily schedule, also in combination with TDF.
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